NeuroScientific (ASX:NSB) reported an 80% response rate in fistulising Crohn’s and is launching a second Phase 2 trial to fast-track Australian approval.
26
Skip to content
Skip to sidebar
Skip to footer
Stocks in Spotlight
View all →-
AI Stocks · Semiconductor stocks SanDisk (NASDAQ:SNDK) The Sell Case Behind a 3,300% AI Memory Rally May 21, 2026 -
Financials · Growth Stocks Powerhouse (ASX:PVL) Why the Re-Rate May Only Be Getting Started May 20, 2026 -
